03 Oct FDA Approves New Indication for Liletta IUD
Liletta Approval Expanded to Include Treatment of Heavy Menstrual Bleeding
In July, Medicines360, a global nonprofit organization with a mission to catalyze equitable access to quality medicines for women, announced that the FDA has approved its supplemental New Drug Application (sNDA) for the Liletta IUD for treatment of Heavy Menstrual Bleeding (HMB) for up to five years in patients who choose intrauterine contraception as their method of contraception.
As a member of Physicians’ Alliance, your practice can access a significant discount on the Liletta IUD through our partnership with AbbVie. Log in to view the current pricing. Not a member? Join now.